Paregoric Kid
07-25-2007, 05:25 AM
there is a very safe medical device called a Cranial Electrotherapy Stimulator which has been shown to be effective to some extent at treating depression, anxiety, insomnia, neuropathic pain, and even drug addiction in some people. it increases endorphins and also raises levels of dopamine, norepinephrine, and serotonin. it works by placing electrodes behind the ears and delivering up to 800 microamperes (very small amount of electricity) to the brain. in some people it can have a euphoric effect that may last up to a few hours and also may produce the sensation of your body feeling lighter or heavier. if you want to build your own go here: http://www.redcircuits.com/Page19.htm here are some interesting notes on CES that have to do with its possible use as a potentiator, a euphoriant, a painkiller, and a withdrawal aid.
"The main property of TCES is to potentiate some drug effects, especially opiates and neuroleptics, during anesthetic clinical procedures. This potentiation effect permits drastic reduction of pharmacological anesthetic agent and reduces post-operative complications." -Transcutaneous cranial electrical stimulation (TCES): a review 1998.
"Indications and Usage: In carefully conducted randomized controlled trials CES has repeatedly shown efficacy in treating mild to moderate primary or secondary anxiety and depressive conditions, normalization of central hemodynamics (systolic and diastolic blood pressure but not peripheral vascular tension) in Stage I hypertension, relieving headache pain (85%) and other types of pain conditions including pain resulting from dental surgery and cancer (35%), and especially in potentiating through centrally-mediated action the effect of analgesic drugs (fentanyl 176%-306%, morphine 174%-306%, alfentanil I 60%-2 15% and dextromoramide 267%-392%), or replacing them altogether and increasing the depth of anesthesia (In one study fentanyl use decreased by 31%.). and increasing attention and the ability to learn new tasks. To a lesser degree CES has been shown effective in relieving primary insomnia (particularly sleep-onset insomnia), mild depression, post-axonic spasticity, minimal brain dysfunction and mood changes subsequent to closed head injury (with corresponding decrease in the need to neuroleptic drugs). Efficacy of CES has been researched in regards to substance abuse recovery (including nicotine and opiate addiction) with mixed results." -CES for neurotransmitter balancing, mood control, IQ gains, sleep, exploration of altered states, peak performance, and much more.
Methadone
16. Gold, M.S., Pottash, A.L.C., Sternbach, H., Barbaban, J., and Annitto, W. Antiwithdrawal effects of alpha methyl dopa and cranial electrotherapy. Paper presented at Society for Neuroscience. 12th Annual Meeting, October, 1982.
Device not specified.
Chronic opiate user inpatients were randomized for this double-blind study and given either alpha methyl dopa (Aldomet) or placebo Aldomet 48 hours after abruptly removing methadone, or CES or placebo CES. Aldomet and CES were both effective in controlling the effects of acute withdrawal. CES was also effective in controlling the effects of protracted withdrawal. No placebo condition was effective. The authors theorized that CES was effective by stimulating -endorphin, which inhibited the noradrenaline activity at the locus ceruleus. No side effects were reported.
17. Gomez, Evaristo and Mikhail, Adib R. Treatment of methadone withdrawal with cerebral electrotherapy (electrosleep). British Journal of Psychiatry (London). 134:111113, 1979. Also in Gomez, Evaristo and Mikhail, Adib R. Treatment of methadone withdrawal with cerebral electrotherapy (electrosleep). Paper presented at the annual meeting of the American Psychiatric Association, Detroit, 1974.
Device: 100 Hz, 2 mS, 0.4 - 1.3 mA, electrodes from the forehead to mastoids
For this single blind study, 28 male heroin addicts, between 18 and 60 years old, undergoing methadone detoxification were selected on the basis of having severe anxiety as measured by the Hamilton Anxiety Scale and Taylor Manifest Anxiety Scale, difficulties in sleeping, willingness to participate in the study for at least 2 weeks in a locked ward, and agreement not to take any tranquilizers or hypnotics while in the study. This was a self medicated withdrawal study in which methadone was given as requested by the patients as needed to control their withdrawal symptoms. The pts were then randomly divided into a CES treatment group (N = 14) who were taking 20 - 60 mg of methadone/day, a placebo group (N = 7) taking 30 to 40 mg/day, and a waiting in line control group (N = 7) taking 25 - 40 mg/day. CES or sham CES was given for 10 days, Monday through Friday, 30 minutes per day. After 6 - 8 CES treatments, methadone intake was 0 in 9 pts, with another 1 at 0 after 10 treatments. 3 were taking 10 - 15 mg after the 10 treatments. The other active pt dropped out of the study after the first treatment. The pts reported feeling restful and having a general feeling of well-being, their sleep was good and undisturbed after 3 treatments. The Taylor Manifest Anxiety Scale scores also came down significantly in the CES group with 7 pts dropping from a mean of 31 before CES to 20 after 10 days (normal is 8 - 18), while the others showed a 25 - 50% reduction. Sham CES pts showed an insignificant change in the mean TMAS scores from 29 to 27. The methadone intake did not change in 4 sham CES pts, and only dropped 5 - 10 mg in the other 3. These pts were anxious and depressed, and complained of difficulty sleeping and somatic problems. The 7 controls also did not do well, TMAS scores increased in 2 cases, was the same in 1, and only decreased 1 - 2 points after 10 days in the remainder. The methadone intake was the same in 3 controls, and decreased in the other 4 after 10 days. These pts were anxious, had difficulty sleeping. HAS scores were also diminished in the CES group but not the placebo or controls. It was noted that with a higher current, the pt felt uncomfortable, but there were no skin burns.
Opiate Abuse
16. Gold, M.S., Pottash, A.L.C., Sternbach, H., Barbaban, J., and Annitto, W. Antiwithdrawal effects of alpha methyl dopa and cranial electrotherapy. Paper presented at Society for Neuroscience. 12th Annual Meeting, October, 1982.
Device not specified.
Chronic opiate user inpatients were randomized for this double-blind study and given either alpha methyl dopa (Aldomet) or placebo Aldomet 48 hours after abruptly removing methadone, or CES or placebo CES. Aldomet and CES were both effective in controlling the effects of acute withdrawal. CES was also effective in controlling the effects of protracted withdrawal. No placebo condition was effective. The authors theorized that CES was effective by stimulating -endorphin, which inhibited the noradrenaline activity at the locus ceruleus. No side effects were reported.
31. Magora, F., Beller, A., Assael, M.I., Askenazi, A. Some aspects of electrical sleep and its therapeutic value. In Wageneder, F.M. and St. Schuy (Eds). Electrotherapeutic Sleep and Electroanaesthesia. Excerpta Medica Foundation, International Congress Series No. 136. Amsterdam, Pages 129-135, 1967.
Device: 30 - 40 Hz, 2 mS, 2 mA, forehead to occipital fossa electrodes
20 hospitalized pts suffering from long-lasting insomnia with anxiety, obsessive and compulsive reactions, morphine and barbiturate addiction and involutional depression were given 2 - 4 CES treatments weekly for 2 - 3 hours a day for a total of 10 - 20 treatments. 5 of the 20 showed no improvement, 11 had sedative effects, and 4 had hypnotic effects. The 15 responders all had normal restoration of their sleep rhythm as measured by EEG. Parallel with the return to a normal sleep pattern, all the other psychiatric signs: anxiety, depression, agitation, delusions, abstinence syndrome, improved so that all these pts were able to leave the hospital. Follow-up has continued for 8 - 12 months after treatment and has revealed no relapse.
Also 9 children (aged 5 - 15 years) suffering from severe, long-lasting bronchial asthma, resistant to conventional treatment, including steroids, were given 3 - 24 (Av. 15) CES treatments once a week for 1 - 2 hours. The asthmatic attacks stopped completely in 3 children and 4 months later the children felt well without taking any drugs. 2 children showed objective improvement, no wheezes were found on examination and, the frequency and severity of wheezing spells were diminished. 1 child showed slight improvement, 2 did not respond at all. None suffered an asthmatic attack for 24 hours following CES. Placebo conditions did not cause any improvement. The authors concluded that it appears that CES may be an adjunct to the treatment of asthma in children. Because of the selection for trial of the most severe cases available to us, resistant to any other known treatment, even slight results are encouraging. It was also noted that no ill-effects were noted on prolonged and repeated observations in dogs and in humans.
"The main property of TCES is to potentiate some drug effects, especially opiates and neuroleptics, during anesthetic clinical procedures. This potentiation effect permits drastic reduction of pharmacological anesthetic agent and reduces post-operative complications." -Transcutaneous cranial electrical stimulation (TCES): a review 1998.
"Indications and Usage: In carefully conducted randomized controlled trials CES has repeatedly shown efficacy in treating mild to moderate primary or secondary anxiety and depressive conditions, normalization of central hemodynamics (systolic and diastolic blood pressure but not peripheral vascular tension) in Stage I hypertension, relieving headache pain (85%) and other types of pain conditions including pain resulting from dental surgery and cancer (35%), and especially in potentiating through centrally-mediated action the effect of analgesic drugs (fentanyl 176%-306%, morphine 174%-306%, alfentanil I 60%-2 15% and dextromoramide 267%-392%), or replacing them altogether and increasing the depth of anesthesia (In one study fentanyl use decreased by 31%.). and increasing attention and the ability to learn new tasks. To a lesser degree CES has been shown effective in relieving primary insomnia (particularly sleep-onset insomnia), mild depression, post-axonic spasticity, minimal brain dysfunction and mood changes subsequent to closed head injury (with corresponding decrease in the need to neuroleptic drugs). Efficacy of CES has been researched in regards to substance abuse recovery (including nicotine and opiate addiction) with mixed results." -CES for neurotransmitter balancing, mood control, IQ gains, sleep, exploration of altered states, peak performance, and much more.
Methadone
16. Gold, M.S., Pottash, A.L.C., Sternbach, H., Barbaban, J., and Annitto, W. Antiwithdrawal effects of alpha methyl dopa and cranial electrotherapy. Paper presented at Society for Neuroscience. 12th Annual Meeting, October, 1982.
Device not specified.
Chronic opiate user inpatients were randomized for this double-blind study and given either alpha methyl dopa (Aldomet) or placebo Aldomet 48 hours after abruptly removing methadone, or CES or placebo CES. Aldomet and CES were both effective in controlling the effects of acute withdrawal. CES was also effective in controlling the effects of protracted withdrawal. No placebo condition was effective. The authors theorized that CES was effective by stimulating -endorphin, which inhibited the noradrenaline activity at the locus ceruleus. No side effects were reported.
17. Gomez, Evaristo and Mikhail, Adib R. Treatment of methadone withdrawal with cerebral electrotherapy (electrosleep). British Journal of Psychiatry (London). 134:111113, 1979. Also in Gomez, Evaristo and Mikhail, Adib R. Treatment of methadone withdrawal with cerebral electrotherapy (electrosleep). Paper presented at the annual meeting of the American Psychiatric Association, Detroit, 1974.
Device: 100 Hz, 2 mS, 0.4 - 1.3 mA, electrodes from the forehead to mastoids
For this single blind study, 28 male heroin addicts, between 18 and 60 years old, undergoing methadone detoxification were selected on the basis of having severe anxiety as measured by the Hamilton Anxiety Scale and Taylor Manifest Anxiety Scale, difficulties in sleeping, willingness to participate in the study for at least 2 weeks in a locked ward, and agreement not to take any tranquilizers or hypnotics while in the study. This was a self medicated withdrawal study in which methadone was given as requested by the patients as needed to control their withdrawal symptoms. The pts were then randomly divided into a CES treatment group (N = 14) who were taking 20 - 60 mg of methadone/day, a placebo group (N = 7) taking 30 to 40 mg/day, and a waiting in line control group (N = 7) taking 25 - 40 mg/day. CES or sham CES was given for 10 days, Monday through Friday, 30 minutes per day. After 6 - 8 CES treatments, methadone intake was 0 in 9 pts, with another 1 at 0 after 10 treatments. 3 were taking 10 - 15 mg after the 10 treatments. The other active pt dropped out of the study after the first treatment. The pts reported feeling restful and having a general feeling of well-being, their sleep was good and undisturbed after 3 treatments. The Taylor Manifest Anxiety Scale scores also came down significantly in the CES group with 7 pts dropping from a mean of 31 before CES to 20 after 10 days (normal is 8 - 18), while the others showed a 25 - 50% reduction. Sham CES pts showed an insignificant change in the mean TMAS scores from 29 to 27. The methadone intake did not change in 4 sham CES pts, and only dropped 5 - 10 mg in the other 3. These pts were anxious and depressed, and complained of difficulty sleeping and somatic problems. The 7 controls also did not do well, TMAS scores increased in 2 cases, was the same in 1, and only decreased 1 - 2 points after 10 days in the remainder. The methadone intake was the same in 3 controls, and decreased in the other 4 after 10 days. These pts were anxious, had difficulty sleeping. HAS scores were also diminished in the CES group but not the placebo or controls. It was noted that with a higher current, the pt felt uncomfortable, but there were no skin burns.
Opiate Abuse
16. Gold, M.S., Pottash, A.L.C., Sternbach, H., Barbaban, J., and Annitto, W. Antiwithdrawal effects of alpha methyl dopa and cranial electrotherapy. Paper presented at Society for Neuroscience. 12th Annual Meeting, October, 1982.
Device not specified.
Chronic opiate user inpatients were randomized for this double-blind study and given either alpha methyl dopa (Aldomet) or placebo Aldomet 48 hours after abruptly removing methadone, or CES or placebo CES. Aldomet and CES were both effective in controlling the effects of acute withdrawal. CES was also effective in controlling the effects of protracted withdrawal. No placebo condition was effective. The authors theorized that CES was effective by stimulating -endorphin, which inhibited the noradrenaline activity at the locus ceruleus. No side effects were reported.
31. Magora, F., Beller, A., Assael, M.I., Askenazi, A. Some aspects of electrical sleep and its therapeutic value. In Wageneder, F.M. and St. Schuy (Eds). Electrotherapeutic Sleep and Electroanaesthesia. Excerpta Medica Foundation, International Congress Series No. 136. Amsterdam, Pages 129-135, 1967.
Device: 30 - 40 Hz, 2 mS, 2 mA, forehead to occipital fossa electrodes
20 hospitalized pts suffering from long-lasting insomnia with anxiety, obsessive and compulsive reactions, morphine and barbiturate addiction and involutional depression were given 2 - 4 CES treatments weekly for 2 - 3 hours a day for a total of 10 - 20 treatments. 5 of the 20 showed no improvement, 11 had sedative effects, and 4 had hypnotic effects. The 15 responders all had normal restoration of their sleep rhythm as measured by EEG. Parallel with the return to a normal sleep pattern, all the other psychiatric signs: anxiety, depression, agitation, delusions, abstinence syndrome, improved so that all these pts were able to leave the hospital. Follow-up has continued for 8 - 12 months after treatment and has revealed no relapse.
Also 9 children (aged 5 - 15 years) suffering from severe, long-lasting bronchial asthma, resistant to conventional treatment, including steroids, were given 3 - 24 (Av. 15) CES treatments once a week for 1 - 2 hours. The asthmatic attacks stopped completely in 3 children and 4 months later the children felt well without taking any drugs. 2 children showed objective improvement, no wheezes were found on examination and, the frequency and severity of wheezing spells were diminished. 1 child showed slight improvement, 2 did not respond at all. None suffered an asthmatic attack for 24 hours following CES. Placebo conditions did not cause any improvement. The authors concluded that it appears that CES may be an adjunct to the treatment of asthma in children. Because of the selection for trial of the most severe cases available to us, resistant to any other known treatment, even slight results are encouraging. It was also noted that no ill-effects were noted on prolonged and repeated observations in dogs and in humans.